Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Adenocarcinoma Non-resectable: early-phase trial registry
1 of 3 indexed Pancreatic Adenocarcinoma Non-resectable trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Pancreatic Adenocarcinoma Non-resectable: 3 US clinical trials tracked, 1 recruiting.
Pancreatic Adenocarcinoma Non-resectable is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Continuity Biosciences, running 1 of these trials.
Enrollment posture brief
Registry condition pancreatic-adenocarcinoma-non-resectable
OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Pancreatic Adenocarcinoma Non-resectable lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Adenocarcinoma Non-resectable on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Adenocarcinoma Non-resectable is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Continuity Biosciences
NCT07481383
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
Jonsson Comprehensive Cancer Center
NCT06090916
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
The Rogosin Institute
NCT01053013
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Adenocarcinoma Non-resectable records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Adenocarcinoma Non-resectable trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Adenocarcinoma Non-resectable page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Pancreatic Adenocarcinoma Non-resectable trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Continuity Biosciences sponsors the most Pancreatic Adenocarcinoma Non-resectable trials on record, review their full trial history before evaluating a specific study. See Continuity Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Adenocarcinoma Non-resectable condition card totals 3 registered trials; most-linked intervention RENCA macrobeads; top US site state West Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.